Structure Therapeutics Inc.
GPCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs. At a $3.45B market cap, Structure Therapeutics Inc. ranks as a mid-cap company within healthcare. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Market Cap
$3.45B
Beta
-1.57
P/E (TTM)
—
P/E (Fwd)
-25.07
EPS (TTM)
$-2.64
EPS (Fwd)
$-1.93
ROE
-15.0%
ROA
-11.6%
Cash
$1.46B
Total Debt
$5.8M
Free CF
-$104.2M
52W Change
151.8%
Annual Financials
Cash vs Debt
With $1.46B in cash and $5.8M in debt, GPCR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$104.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -15.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Structure Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, GPCR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Structure Therapeutics Inc. and its sector.